


*A monthly report summarizing the Life Science transactions and trends in Washington State.*

Washington State Transactions

## Washington State Transactions by Industry



### News highlights:

- Clarity Health was acquired by SCI Solutions. This acquisition creates one of the largest referral management and care coordination software firms in the industry, serving more than 10,000 physician practices and 700 hospitals, health systems, and imaging centers in 275 geographic markets across the United States.
- Presage Biosciences has in-licensed Phase I oral cancer drug voruciclib from India’s Piramal Enterprises to test its intratumoral microinjection platform, which the company claims can accelerate drug development.
- Adaptimmune has partnered with Seattle-based Universal Cells to develop off-the-shelf T-cell immunotherapies to fight cancer. The deal starts with \$5.5 million and up to \$41 million in milestones.
- Nohla Therapeutics spun out of the Fred Hutch Cancer Research Center to develop an alternative to bone marrow transplants, and has secured \$20 million in venture commitments. The company signed a deal with Fred Hutch that gives it worldwide rights to technology that uses re-engineered umbilical cord blood graft to craft a patient-agnostic product that could be used in lieu of donor marrow.

### Deal highlights:

- **Aminex Therapeutics** \$4 million (Series A)
- **Mpirica Health** \$400,000 (Equity)
- **Qliance Medical Management** \$450,000 (Equity)
- **Implicit Bioscience** \$50,800 (Equity)
- **M3 Biotechnology** \$3.5 million (Equity)
- **OtoNexus Medical Technologies** \$1.4 million (Debt)
- **Universal Cells** \$5.5 million (Partnership)


**November 2015 total:** \$9,803,880  
**2015 running total (Jan – Dec 5<sup>th</sup>):** \$3,236,164,462

November 2015

## Medical Technology Transactions from 2013 to 2015

Medical technology encompasses a wide range of healthcare products used to diagnose, monitor and/or treat diseases or medical conditions. From 2013 to 2015, the number of medical technology deals have remained consistent, but amounts and sources of funding have increased.


Medical Technology Transactions by Deal Size



**Over 80% of medical technology deals from 2013 to 2015 have been under \$10 million.**

- With over 60% of deals being under \$5M including about 20% of deals up to \$500,000
- Deals over \$50M account for about 6% of all deals but represent the majority of transactions:
  - In 2013:
    - Ekos \$180M (M&A | BTG)
    - NanoString Technologies \$54M (IPO)
  - In 2014:
    - Adaptive Biotechnologies \$105 M (Series C&D)
    - Integrated Diagnostics \$30M (Series B)
    - Cardiac Dimensions \$28.5M (Venture Capital)
  - In 2015:
    - RF Surgical Systems \$235M (M&A | Medtronic)
    - Adaptive Biotechnologies \$289 M (Series E&F)

Medical Technology Transactions by Type



**Sources of investment in medical technology have varied from 2013 to 2015.**

In 2013, M&As accounted for over 56% of all transactions, which is attributed to the acquisition of Ekos by BTG. There was more venture capital activity in 2014 and 2015, 52% and 79% respectively, which is attributed to various deals.

\*As of December 5, 2015

### Who's investing in medical technology in Washington State?

#### Top Deals:

Cadence Biomedical	
Alliance of Angels	BioPacific Ventures
Frontier Angel Group	HealthTech Capital

Integrated Diagnostics	
Asset Management Ventures	Baird Capital
InterWest Partners	Wellcome Trust

Cardiac Dimensions	
Arboretum Ventures	Aperture Ventures
Lumira Capital	M.H. Carnegie & Co.

NanoString Technologies	
Accelerator Corp	Clarus Ventures
Celgene	Draper Fisher Jurvetson

This report is prepared by WBBA Commercialization Manager, Yesenia Green, PhD, [yesenia@washbio.org](mailto:yesenia@washbio.org).

\*\*The data in this report is compiled from publicly disclosed information and is not independently verified by WBBA.



## Washington-based Life Science Transactions 2013

Date	Company	Type	Amount
01/03/13	Qliance Medical Management	Series D	\$8,650,000
01/04/13	RF Surgical Systems	Series A	\$120,000
01/30/13	Immune Design	3rd installment series B	\$10,625,000
01/31/13	FlexMinder	Series A	\$1,200,000
02/08/13	Kineta	Venture Equity	\$2,737,052
02/14/13	X2 Biosystems	Undisclosed	\$2,000,000
02/15/13	Healionics	Undisclosed	\$50,000
02/20/13	Miribilibi Medica	Undisclosed	\$120,000
02/20/13	Ventec Life Systems	Venture Equity	\$6,800,000
02/22/13	Blaze Bioscience	Series A	\$8,500,000
02/22/13	Endogastric Solutions	Debt	\$10,000,000
02/27/13	Resolve Therapeutics	Partnership	\$8,000,000
03/01/13	Cadence Biomedical	Venture Equity	\$213,000
04/01/13	EveryMove	Series A	\$3,500,000
04/03/13	Avado	Seed equity	\$1,000,000
03/05/13	PreSage Biosciences	Partnership	\$13,000,000
03/12/13	Appature	Acquisition	NA
03/12/13	Spiral Genetics	Venture Equity	\$3,200,000
03/25/13	Theraclone Sciences	Series B	\$14,000,000
04/02/13	Cardiac Dimensions	Debt	\$2,730,000
04/02/13	Cerevast Therapeutics	Venture Equity	\$1,500,000
04/11/13	Atossa Genetics	Venture Equity	\$100,000
04/17/13	Beat BioTherapeutics	Debt	\$2,500,000
04/18/13	NuvoMed	Equity	\$485,000
04/19/13	Miribilibi Medica	Debt	\$100,000
05/13/13	NanoString Technologies	Venture Equity	\$150,000
05/23/13	Cardeas Pharma	Series B	\$34,000,000
05/23/13	Valant Medical Solutions	Venture Equity	\$784,000
05/24/13	Remote Medical International	Venture Equity	\$8,000,000
05/24/13	Ekos	Acquisition	\$180,000,000
05/28/13	VentriPoint	Debt	\$750,000
05/30/13	Cadence Biomedical	Grant	\$1,000,000
05/30/13	Oncothyreon	Stock sale	\$10,000,000
06/03/13	AVM Biotechnology	Venture Equity	\$708,000
06/05/13	Mobisante	Venture Equity	\$4,200,000
06/06/13	Cheetah Medical	Venture Equity	\$14,500,000
06/12/13	Immune Design	Partnership	\$10,000,000
06/14/13	Miribilibi Medica	Venture Equity	\$7,000,000
06/18/13	Exo Labs	Undisclosed	\$836,000
06/20/13	X2 Biosystems	Venture Equity	\$1,200,000
06/25/13	Seattle Genetics - Bayer deal	Partnership	\$20,000,000
06/26/13	NanoString Technologies	IPO	\$54,000,000
06/27/13	Lifecom	Series A	\$1,100,000
06/28/13	Blaze Biosciences	Series B	\$8,100,000
07/12/13	PhaseRx	Debt	\$500,000
07/12/13	X2 Biosystems	Debt	\$720,000
08/15/13	Project Violet	Undisclosed	\$20,000,000
08/16/13	Tissue Regeneration Systems	Venture Equity	\$4,600,000
08/19/13	Allozyne	Debt	\$2,500,000
09/03/13	Oncofactor	Venture Equity	\$1,000,000
09/03/13	Alpine Bioventures	Equity	\$5,000,000
09/09/13	Stratos Genomics	Venture Equity	\$2,000,000
09/16/13	Adaptive Biotechnologies	Grant	\$2,530,000
09/20/13	Integrated Diagnostics	Equity	\$1,500,000
10/03/13	PhaseRx	Debt	\$1,400,000
10/10/13	Kineta	Venture Equity	\$760,000
10/15/13	Qliance Medical Management	Venture Equity	\$5,500,000
10/16/13	Sound Pharmaceuticals	Venture Equity	\$6,000,000
10/16/13	Cardiac Dimensions	Debt	\$555,000
10/21/13	Kona Medical	Venture Equity	\$10,000,000
10/29/13	Avado	Acquisition	\$25,000,000
10/30/13	Immune Design	Venture Equity	\$49,000,000
11/04/13	Kineta	Grant	\$6,800,000
11/15/13	Cell Therapeutics	Partnership	\$60,000,000
11/26/13	Cerevast Therapeutics	Debt	\$1,780,000
11/27/13	Impel NeuroPharma	Venture Equity	\$2,640,000
12/05/13	Clarity Health	Series B	\$6,600,000
12/03/13	Blaze Bioscience	Series B*	\$900,000
12/05/13	Juno Therapeutics	Series A	\$120,000,000
12/10/14	Integrated Diagnostics	Seed equity	\$300,000
12/27/13	X2 Biosystems	Venture Equity	\$5,000,000
<b>2013 Total</b>			<b>\$800,043,052</b>

## Washington-based Life Science Transactions 2014

Date	Company	Type	Amount
01/07/14	Cardiac Dimensions	Debt	\$367,000
01/08/14	Seattle Genetics	Partnership	\$25,000,000
01/13/14	Juno Therapeutics	Series A extension	\$25,000,000
01/13/14	ActX	Seed equity	\$1,900,000
01/14/14	NovuMed	Undisclosed	\$535,000
01/21/14	Seattle Genetics	Partnership	\$9,000,000
02/04/14	Acucela	IPO (Japan)	\$162,000,000
02/12/14	Cardiac Dimensions	Debt	\$456,000
02/12/14	Nativis	Venture Equity	\$9,160,000
03/05/14	Immunexpress	Venture Equity	\$6,000,000
03/14/14	Kineta	Venture Equity	undisclosed
03/14/14	Nortis	Undisclosed	\$1,200,000
03/17/14	CadenceMD	Debt	\$55,000
03/20/14	Cardiac Dimensions	Debt	\$380,000
03/25/14	Clarity Health	Venture Equity	\$836,000
03/25/14	BioLife Solutions	IPO	\$15,400,000
03/25/14	FlexMinder	Series A	\$1,200,000
03/26/14	KinDex Pharmaceuticals	Series A	\$5,000,000
04/07/14	Adaptive Biotechnologies	Series C&D	\$105,000,000
04/09/14	Oricula Therapeutics	Seed equity	\$122,000
04/10/14	Tissue Regeneration Systems	Debt	\$1,500,000
04/14/14	JeNu Biosciences	Debt	\$1,480,000
04/14/14	Etubics	Seed	\$4,400,000
04/16/14	Cardiac Dimensions	Venture Equity	\$20,000,000
04/18/14	X2 Biosystems	Debt	\$2,510,000
04/24/14	Juno Therapeutics	Series A extension	\$31,000,000
04/29/14	Integrated Diagnostics	Debt	\$17,000,000
04/29/14	Integrated Diagnostics	Series B	\$30,250,000
05/08/14	Alder Biopharmaceuticals	IPO	\$80,000,000
05/13/14	Stratos Genomics	Series B	\$10,000,000
05/14/14	PharmalN	Venture Equity	\$1,500,000
05/15/14	AVM Biotechnology	Series B	\$1,500,000
05/16/14	Kineta	Equity	\$1,627,498
06/06/14	NanoString Technologies	Partnership	\$5,750,000
06/15/14	Cardiac Insight	Series B	\$7,000,000
07/01/14	Pregenen	Acquisition	\$20,000,000
07/11/14	Nortis	Venture Equity	\$1,000,000
07/15/14	Valant Medical	Venture Equity	\$11,000,000
07/18/14	ActX	Seed	\$750,000
07/21/14	Nativis	Undisclosed	\$2,319,000
07/25/14	Immune Design	IPO	\$60,000,000
07/29/14	Accelerator Corporation	Venture Equity	\$51,100,000
07/29/14	Amgen	Closing WA Offices	
07/30/14	Theraclone Sciences	Partnership	undisclosed
07/30/14	Array Health	Debt	\$100,000
07/30/14	Jintronic	Debt	\$772,500
08/04/14	Juno Therapeutics	Series B	\$134,000,000
08/07/14	Immune Design	License	\$168,000,000
08/11/14	Alpine BioSciences	Acquisition	\$27,000,000
08/15/14	Carena	Debt	\$1,995,000
08/21/14	Immusoft	Series A	\$2,300,000
09/02/14	Clarity Health	Venture Equity	\$1,059,352
09/03/14	NovoNordisk	Closing Inflammatory Research Center	
09/10/14	Seattle Genetics	License	\$11,000,000
09/15/14	Tissue Regeneration Systems	Debt	\$500,000
09/23/14	VentriRx Pharmaceuticals	Venture Equity	\$19,300,000
09/26/14	Array Health	Series A	\$13,000,000
10/07/14	Cardiac Dimensions	Venture Equity	\$8,500,000
10/08/14	Blaze BioScience	NCI SBIR Phase II Funding	\$1,500,000
10/09/14	Mirador Biomedical	Acquisition	undisclosed
10/27/14	Limeade	Series C	\$25,000,000
11/05/14	Vicis	Seed	\$2,000,000
11/19/14	IDRI	Contract	\$3,600,000
11/21/14	Aortica	Series A	\$7,000,000
12/09/14	Allen Institute for Cell Science	Paul Allen Donation	\$100,000,000
12/19/14	Juno Therapeutics	IPO	\$264,600,000
12/30/14	Oncogenex	Venture Equity	\$27,000,000
12/30/14	Cerevast Therapeutics	Venture Equity	\$10,000,000
<b>2014 Total</b>			<b>\$1,558,524,350</b>

This report is prepared by WBBA Commercialization Manager, Yesenia Green, PhD, [yesenia@washbio.org](mailto:yesenia@washbio.org).

*\*The data in this report is compiled from publicly disclosed information and is not independently verified by WBBA.*